Pharmacogenomics and schizophrenia

European Journal of Pharmacology

Volumn 410, Issue 2-3, 2000, Pages 227-241

  Kawanishi, Yoichi ^a   Tachikawa, Hirokazu ^a   Suzuki, Toshihito ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

DNA microarray; Genome wide scanning; Pharmacogenetics; Pharmacogenomics; Schizophrenia; Single nucleotide polymorphism

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DIHYDROERGOTAMINE; DOPAMINE RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN RECEPTOR; SUMATRIPTAN; THIORIDAZINE; ZUCLOPENTHIXOL;

ARTICLE; DNA MICROARRAY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; EXTRAPYRAMIDAL SYMPTOM; GENE FREQUENCY; GENE MAPPING; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; ORTHOSTATIC HYPOTENSION; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA; SEDATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHENOTYPE; SCHIZOPHRENIA;

EID: 0034723041     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00817-7     Document Type: Article

References (163)

1. Schizophrenia: The fundamental questions
2. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients
3. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia
4. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype
5. Suspension arrays for high throughput, multiplexed single nucleotide polymorphism genotyping
6. Neurotransmitter-related genes and antipsychotic response: Pharmacogenetics meets psychiatric treatment
7. 2A receptor gene
8. Cytochrome P450D6 genotype does not determine response to clozapine
9. 2A receptor and clinical response to clozapine
10. Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response
11. 2A receptor gene and response to clozapine
12. 2A receptors and clozapine response
13. Pharmacogenetic prediction of clozapine response
14. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia
15. Dopamine D4 receptor repeat: Analysis of different native and mutant forms of the human and rat genes
16. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants
17. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia
18. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: Association with tardive dyskinesia in schizophrenia
19. A complex program of striatal gene expression induced by dopaminergic stimulation
20. 5A gene in depression, psychosis and antipsychotic response
21. The essence of SNPs
22. Genome II: The next frontier
23. 1A receptor variant with the Ile28Val substitution in the extracellular domain
24. 1B receptor
25. 1Dβδ receptor
26. Effect of chlorpromazine and haloperidol on the formation of 3-methoxytyramine in mouse brain
27. Enzymatic deficiency in primaquine-sensitive erthrocytes
28. 4 receptor gene in psychotic patients
29. Accessing genetic information with high-density DNA arrays
30. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia
31. Detection of four polymorphic sites in the human dopamine D1 receptor gene (DRD1)
32. Protein, nucleotide identification of two novel polymorphisms and a rare deletion variant in the human dopamine D4 receptor gene
33. Systemic screening for mutations in the 5′-regulatory region of the human dopamine D1 receptor (DRD1) gene in patients with schizophrenia and bipolar affective disorder
34. Pharmacogenetics of schizophrenia
35. Polymorphisms of the dopamine D4 receptor and response to antypsychotic drugs
36. Microarrays and macroconsequences
37. The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two defferent ethnic groups
38. Polymorphic cytochrome P450 and drugs in psychiatry
39. 5 dopamine receptor missense and nonsense variants: Differences in dopamine binding affinities
40. 2 dopamine receptor missense variants
41. 2 dopamine receptor missense variants
42. Association between schizophrenia and homozygosity at the dopamine D3 receptor gene
43. Genetically variable metabolism of antidepressants and neuroleptic drugs in man
44. Nomenclature for human CYP2D6 alleles
45. DNA microarrays in drug discovery and development
46. Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: A generalization of Steen's study on DRD3 and tardive dyskinesia
47. 1A gene
48. 2A) receptor gene: Identification of two naturally occurring receptor variants and association analysis in schizophrenia
49. 7) receptor gene: Genomic organization and systematic mutation screening in schizophrenia and bipolar affective disorder
50. Genetic control of isoniazid metabolism in man
51. Pharmacogenomics: Translating functional genomics into rational therapeutics
52. Metabolism, phaarmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs
53. Scanning of the dopamine D1 and D5 receptor genes by REF in neuropsychiatric patients reveals a novel missense change at ahighly conserved amino acid
54. Chronical haloperidol and clozapine treatment in rats: Differential RNA display analysis, behavioral studies and serum level determination
55. Olanzapine. A pharmacoeconomic review of its use in schizophrenia
56. Ethnicity and antipsychotic response
57. No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis
58. Natural structural variants of human serotonin receptors
59. Resequencing and mutational analysis using oligonucleotide microarrays
60. Determination of ancestral alleles for human single-nucleotide polymorphisms using high-density oligonucleotide arrays
61. CYP2D6 mutations and therapeutic outcome in schizophrenic patients
62. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial
63. Investigation of genetic risk factors associated with alcoholism
64. Maganese superoxide dismutase gene polymorphism and schizophrenia. Relation to tardive dyskinesia
65. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis
66. Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia
67. Discovery, scoring and utilization of human single nucleotide polymorphisms: A multidisciplinary problem
68. A structural polymorphism of human dopamine D2 receptor, D2(Ser311->Cys)
69. Identification of a naturally occurring Pro15-Ser15 substitution in the serotonin5A receptor gene in alcoholics and healthy volunteers
70. New atypical antipsychotic medications
71. Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation
72. 2A gene and schizophrenia: Relation to phenotype and drug response variability
73. Familial incidence of low pseudocholinesterase level
74. Genetic polymorphism for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia
75. 1A receptor gene and association analysis in schizophrenia
76. The molecular genetics of schizophrenia: Progress so far
77. Dopamine D4 receptor gene polymorphisms: Relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects
78. Dopamine D1 receptor gene polymorphism and schizophrenia
79. Dopamine D3 receptor gene variants and substance abuse in schizophrenia
80. 1A) variant found in a Tourette's syndrome patient
81. 2c receptor gene (HTR2C)
82. Screening the dopamine D1 receptor gene in 131 schizophrenics and eight alcoholics: Identification of polymorphisms but lack of functionally significant sequence changes
83. Dopamine D4 receptor variant in Africans, D4valine194glycine, is insensitive to dopamine and clozapine: Report of a homozygous individual
84. Interethnic differences in drug metabolism: Influence of genetic and environmental factors on debrisoquine hydroxylation phenotype
85. Proposed schizophrenia-related gene polymorphism: Expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system
86. 2A receptor gene and the antipsychotic response to clozapine
87. 2C Cys23Ser polymorphism
88. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: A haplotype relative risk study and association with clozapine response
89. Pharmacogenomics: The genomics of drug response
90. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution
91. Drug firms to create public database of genetic mutations
92. 2A receptor and response to clozapine
93. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients
94. Pharmacogenetics of antipsychotic treatment: Lessons learned from clozapine
95. The use of single-nucleotide polymorphism maps in pharmacogenomics
96. Role of serotonin in the action of atypical antipsychotic drugs
97. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients in schizophrenia
98. Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq 1A polymorphism of DRD2 gene
99. At issue: Genes, experience, and chance in schizophrenia-positioning for the 21st century
100. Behavioural pharmacology of the new generation of antipsychotic agents
101. 1A receptor: Glycine 22 to serine 22 and isoleucine 28 to valine 28
102. Polymorphisms in drug-metabolizing enzymes: What is their clinical relevance and why do they exist?
103. Human dopamine D4 receptor gene: Frequent occurrence of a null allele and observation of homozygosity
104. Identification of genetic variation in the human serotonin 1Dβ receptor gene
105. 2A receptor and response to clozapine
106. Schizophrenia: Dopamine D1 receptor sequence is normal, but has DNA polymorphisms
107. Functional polymorphism of -141 C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia
108. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics
109. Genetic association in analysis between CYP2D6* 2 allele and tardive dyskinesia in schizophrenic patients
110. A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia
111. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms
112. 1Dα autoreceptor gene (HTR1D) on chromosome 1 using a silent polymorphism in the coding region
113. 2A receptor influences amplitude and timing of intracellular calcium mobilization
114. Haloperidol concentrations elevated in Chinese patients
115. Drug metabolism and atypical antipsychotics
116. Genetic variation of CNS receptors - A new perspective for pharmacogenetics
117. Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine
118. Efficacy and side-effects of clozapine: Testing for association with allelic variation in the Dopamine D4 receptor gene
119. 2C receptor
120. Application of pharmacogenetics to psychotic disorders: The first consensus conference
121. Dopamine D3 receptor variant and tardive dyskinesia
122. Pharmacogenetics and the practice of medicine
123. 1A receptor
124. Genomics and drugs: Finding the optimal drug for the right patient
125. Pharmacogenomics
126. Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes
127. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone
128. Dopamine D4 receptor variant, D4GLYCINE194, in Africans, but not in Caucasians: No association with schizophrenia
129. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia
130. Microchip arrays put DNA on the spot
131. Dopamine D4 receptor subtypes and response to clozapine
132. Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients
133. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia
134. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients
135. 1E) receptor protein points to its evolutionary conservation
136. Systematic screening for mutations in the human serotonin 1F receptor gene in patients with bipolar affective disorder and schizophrenia
137. 5A receptor gene: Systematic screening for DNA sequence variation and linkage mapping on chromosome 7q34-q36 using a polymorphism in the 5′ untranslated region
138. A cluster of single nucleotide polymorphism in the 5′-leader of the human dopamine D3 receptor gene (DRD3) and its relationship to schizophrenia
139. The D5 dopamine receptor gene in schizophrenia: Identification of a nonsense change and multiple missense changes but lack of association with disease
140. 2C receptor gene
141. 2C) gene
142. Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects
143. Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions
144. 2A and schizophrenia plus identification of new polymorphisms in the promoter
145. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients
146. From gels to chips: "Minisequencing" primer extension for analysis of point mutations and single nucleotide polymorphisms
147. Schizophrenia: Pathophysiological mechanisms - A synthesis
148. Recent advances in genetic research on schizophrenia
149. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes
150. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
151. Multiple dopamine D4 receptor variants in the human population
152. Moderne Probleme der Humangenetik
153. 1: A psychostimulant-regulated gene essential for establishing cocaine sensitization
154. Meta-analysis of association between the 5-HT2a receptor T102C polymorphism and schizophrenia
155. Atypical antipsychotic agents: A critical review
156. 1A receptor gene
157. 1A receptor is intact in mood disorders
158. Serotonin-6 receptor variant (C267T) and clinical response to clozapine
159. Expression and characterization of a dopamine D4R variant associated with delusional disorder
160. Mapping of complex traits by single-nucleotide polymorphisms